NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
NRx Pharmaceuticals announced that strategic partner Emobot Health presented late-breaking clinical validation data for its EMOCARE digital biomarker at the ASCP 2026 annual meeting. A pooled analysis of three prospective studies showed EMOCARE achieved a 0.895 concordance correlation with clinician-rated MADRS scores and a 0.834 sensitivity correlation with PHQ-9 symptom changes, validating its accuracy as a passive monitoring tool.
Key figures
- Phq9 p value
- <0.001
- Madrs p value
- 0.016
- Madrs concordance r
- 0.895
- Phq9 sensitivity rho
- 0.834
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.